about
Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Pacific Region (MUSIC OS-AP): Design of a multinational, prospective, observational study examining the impact of gastrointestinal events on osImproving Outcome of Psychosocial Treatments by Enhancing Memory and Learning.Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practiceImplementing adherence to osteoporosis treatments.Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment.Adoption of once-monthly oral bisphosphonates and the impact on adherence.Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial.Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribingAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisOnce-monthly risedronate for postmenopausal osteoporosisBisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.Intravenous bisphosphonates for postmenopausal osteoporosis.Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.Addition of fructooligosaccharides and dried plum to soy-based diets reverses bone loss in the ovariectomized rat.Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational StudyClinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonatesLearning cognitive behavior therapy.Comparative gastrointestinal safety of weekly oral bisphosphonates.Severe polyarthritis secondary to zolendronic acid: a case report and literature reviewCorrelates of use of antifracture therapy in older women with low bone mineral density.Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare populationMedical treatment of osteoporotic vertebral fractures.Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional studyOsteoporosis medication profile preference: results from the PREFER-US studyOral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.Medication burden of Saudi Arabian women receiving antiresorptive therapyHow can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysisPatients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women.The development and validation of the Memory Support Rating Scale.Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosisPatient-reported barriers to osteoporosis therapy.Implementing clinical practice guidelines about health promotion and disease prevention through shared decision makingEmerging pharmacologic therapies for osteoporosis.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs.Osteoporosis medication adherence: physician perceptions vs. patients' utilization.
P2860
Q30400736-8BC2CD0B-67AF-42AA-AB50-FC408A827515Q30417837-DA513190-2FB9-458D-A651-79CF197C4FC3Q30492459-C3448148-A06F-47F7-ACD8-615082E502D4Q33610273-9EEBBD72-136E-4FFB-B315-DA5D18E68D4EQ33667473-43549DED-EF3E-4F0A-BBE1-604DB3AAB610Q33701964-769327F8-5107-49C0-9F68-A936427D9A1DQ33746674-1D8555E5-D333-4BD1-84B9-B0CBB53D22DCQ33874953-67D2B562-83AA-4D71-AC16-52165F051B76Q34158441-25FB3998-D4E4-4756-BE30-38F56D177D56Q34272000-2C03CD2B-DF92-4473-995D-B05683B95ADBQ34305113-EA4ED838-1671-429E-B3B5-5EB368B88C94Q34863964-CA54A8D5-304C-46DF-B380-0B7517ED9410Q35026446-85688418-F6C7-456C-95A7-673FC1A7FB48Q35077750-FAB66B8A-A5D7-4F24-A8EB-2325F1A63B1FQ35092609-63438885-F3C1-4ACC-93AD-F6A49389B566Q35109171-2B0B0DD0-40BA-4DB2-BEDE-CB83AAA72529Q35371081-66599DB0-1832-404E-A57C-D3444BE5BFA3Q35533455-12CD9723-133D-4E17-BBA4-C4BF8E5609D1Q35589457-C55F39CF-4B90-4419-B88F-0BAAE8900149Q35670045-5143FCC6-9AA8-49C1-9E94-5CB362F19DB5Q35747575-007F3767-9DBC-4723-B7C4-00CF245DA277Q35901389-91B29B1B-467E-43A5-8D83-869DCB53CCF1Q35968876-11D42C81-FF95-4AB1-886A-6244C2AD8017Q36059589-1C47BBBA-72AA-4F0D-987B-A65A85728DF8Q36073613-6DBFC76C-303B-459C-9738-C888701305D9Q36088579-CFF3F602-7FA0-49BB-B9C3-9464AE5DA758Q36283739-0E3957C3-917C-4BC7-B766-6EA6424FC932Q36311638-5AA00438-F456-49A1-BEF5-DAC753298380Q36492900-121385B9-C103-4AC9-A469-5D362431C4E8Q36502735-63D85CC2-FEC4-4006-ABE9-91679ECD0650Q36516518-596CB9A6-69EC-43A1-A99E-042E6696AE74Q36712037-64617499-2FB3-4988-9FE5-44C1C72FAC3EQ36792733-C99C3C14-38F2-460B-92A5-98DEF733F2CCQ36795687-AC3776E5-CBB8-4D14-A4EE-2A3468FD1772Q36853473-28C3570B-BDC9-4B5E-90D2-A054DD0AFFA4Q36874923-288A2643-4310-4AA4-9028-B035E5895701Q36944034-D6C2DC41-2B05-4474-A61B-C5EB5C691BA7Q36959809-62B2F56A-7092-4C11-8987-61ECA0B13789Q36979427-896CA366-19FE-4CC1-ABFC-73AA49DABD15Q37183237-C29DFE4B-25D7-44A6-BCB4-092D175F84EF
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Early discontinuation of treatment for osteoporosis.
@en
Early discontinuation of treatment for osteoporosis.
@nl
type
label
Early discontinuation of treatment for osteoporosis.
@en
Early discontinuation of treatment for osteoporosis.
@nl
prefLabel
Early discontinuation of treatment for osteoporosis.
@en
Early discontinuation of treatment for osteoporosis.
@nl
P2093
P1476
Early discontinuation of treatment for osteoporosis.
@en
P2093
Alice R Pressman
Anna N A Tosteson
Bruce Ettinger
Cristina S Hammond
G Thomas Ray
Gwen M Hebert
Margaret R Grove
Megan M Moncur
P304
P356
10.1016/S0002-9343(03)00362-0
P407
P577
2003-08-01T00:00:00Z